— Know what they know.
Not Investment Advice

EPZM NASDAQ

Epizyme, Inc.
1W: -0.7% 1M: -0.7% 3M: +214.3% 1Y: -73.2% 3Y: -87.5% 5Y: -88.8%
$1.47
Last traded 2022-08-11 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$227M -9.9% ▼
Capital Expenditures
$486K +99.0% ▲
5Y CAGR: -4.9%
Free Cash Flow
-$227M +11.6% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$70M -343.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
— Operating Activities —
Net Income-$134M-$124M-$170M-$232M-$251M
Depreciation & Amort.$2M$1M$840K$4M$5M
Stock-Based Comp.$11M$12M$18M$28M$27M
Change in Working Capital$909K-$10M$7M-$8M-$156K
Other Non-Cash Items$265K-$2M-$3M$2M-$8M
Operating Cash Flow-$120M-$122M-$147M-$206M-$227M
— Investing Activities —
Capital Expenditures-$984K-$299K-$594K-$51M-$486K
Acquisitions (Net)$0$0$0$50M$50M
Investment Purchases-$126M-$299M-$505M-$276M-$263M
Investment Sales$241M$196M$420M$313M$389M
Other Investing$0$0$0-$50M-$50M
Investing Cash Flow$113M-$103M-$85M-$15M$125M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$156M$84M$286M$250M$31M
Financing Cash Flow$156M$84M$286M$250M$31M
Net Change in Cash$149M-$140M$54M$29M-$70M
Cash End of Period$227M$87M$141M$170M$100M
Free Cash Flow-$121M-$122M-$148M-$257M-$227M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms